AmpliPhi Biosciences Corporation (NYSEMKT:APHB) Files An 8-K Results of Operations and Financial Condition

Item2.02 Results of Operations and Financial Condition.

On May 15, 2017, we announced our financial results for the
quarter ended March 31, 2017 in the press release attached hereto
as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 2.02 and the attached Exhibit 99.1
is being furnished and shall not be deemed filed for the purposes
of Section 18 of the Securities and Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that Section.
The information in this Item 2.02 and the attached exhibit shall
not be incorporated by reference into any registration statement
or other document to the Securities Act of 1933, as amended.

Item9.01 Financial Statements and Exhibits.

(d) Exhibits.

About AmpliPhi Biosciences Corporation (NYSEMKT:APHB)

AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The Company is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates include AB-SA01, AB-PA01 and AB-CD01.

AmpliPhi Biosciences Corporation (NYSEMKT:APHB) Recent Trading Information

AmpliPhi Biosciences Corporation (NYSEMKT:APHB) closed its last trading session 00.00 at 1.04 with 1,555,943 shares trading hands.